Clinical Trial Update: Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden [Phase 1, Phase 2]

View source ↗

Summary

Early-phase clinical trial investigating decitabine-primed tandem CD19/CD20 CAR T cells combined with epigenetic agents for aggressive relapsed/refractory B-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Relapsed or Refractory B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Decitabine-primed Tandem CD19/CD20 CAR T Cells
• epigenetic agents

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden | Phase 1, Phase 2 | Status: UNKNOWN